Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.80 |
| ▸ | MMP8 | P22894 | 11/20 | 0.80 |
| ▸ | MMP1 | P03956 | 7/20 | 0.71 |
| ▸ | FCER2 | P06734 | 4/20 | 0.71 |
| ▸ | MMP2 | P08253 | 11/20 | 0.67 |
| ▸ | MMP7 | P09237 | 3/20 | 0.60 |
| ▸ | MMP12 | P39900 | 2/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.60 |
| ▸ | MMP3 | P08254 | 3/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558630 | 1.00 | MMP9 (0.80) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5556787 | 0.89 | ERAP2 (0.69) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5557763 | 0.88 | MMP8 (0.64) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5552431 | 0.88 | MMP2 (0.76) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5552447 | 0.87 | MMP9 (0.74) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5552444 | 0.87 | MMP9 (0.74) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5552823 | 0.86 | MMP9 (0.62) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL4840160 | 0.86 | MMP9 (0.60) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5558476 | 0.85 | MMP9 (0.60) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5552428 | 0.85 | MMP9 (0.68) | MMP9MMP8MMP1FCER2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP8 24/4885MMP1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.